Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.44 USD
Change Today +0.01 / 0.41%
Volume 429.1K
SNSS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

sunesis pharmaceuticals inc (SNSS) Snapshot

Open
$2.44
Previous Close
$2.43
Day High
$2.48
Day Low
$2.35
52 Week High
08/27/14 - $8.46
52 Week Low
10/13/14 - $1.00
Market Cap
178.0M
Average Volume 10 Days
680.3K
EPS TTM
$-0.60
Shares Outstanding
73.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUNESIS PHARMACEUTICALS INC (SNSS)

Related News

No related news articles were found.

sunesis pharmaceuticals inc (SNSS) Related Businessweek News

No Related Businessweek News Found

sunesis pharmaceuticals inc (SNSS) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.

39 Employees
Last Reported Date: 03/12/15
Founded in 1998

sunesis pharmaceuticals inc (SNSS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $488.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $390.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $420.9K
Compensation as of Fiscal Year 2014.

sunesis pharmaceuticals inc (SNSS) Key Developments

Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

Sunesis Pharmaceuticals, Inc. announced that two poster presentations describing results from the VALOR trial will be presented at the 20th Congress of the European Hematology Association (EHA) being held June 11 – 14, 2015, at the Reed Messe Wien Exhibition & Congress Center in Vienna, Austria. VALOR is a randomized, double-blind, placebo-controlled Phase 3 trial which enrolled 711 adult patients with first relapsed or refractory AML at 124 leading sites in 15 countries. Patients were stratified for age, geographic region and disease status and randomized one to one to receive either vosaroxin and cytarabine or placebo and cytarabine.

Sunesis Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Sunesis Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Total revenue for the three months ended March 31, 2015 was $854,000, as compared to $1,995,000 for the same period in 2014. Revenue in each period was primarily due to deferred revenue recognized related to the royalty agreement with Royalty Pharma. The company reported loss from operations of $8,769,000 for the three months ended March 31, 2015 as compared to $8,974,000 for the same period in 2014. Net loss was $9,128,000 or $0.13 per basic and diluted share for the three months ended March 31, 2015 as compared to $14,573,000 or $0.26 per basic and diluted share for the same period in 2014. Cash used in operations was $11.6 million for the three months ended March 31, 2015 as compared to $11.4 million for the same period in 2014.

Sunesis Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

Sunesis Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNSS:US $2.44 USD +0.01

SNSS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.0070 USD 0.00
POZEN Inc $6.71 USD +0.04
View Industry Companies
 

Industry Analysis

SNSS

Industry Average

Valuation SNSS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.9x
Price/Book 10.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit www.sunesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.